Abstract
Objective: To investigate the effect of letrozole on patients undergoing postoperative endocrine therapy for breast cancer. Methods: The period of the study was from June 2021 to January 2023, and 40 patients who were undergoing postoperative endocrine therapy for breast cancer were grouped into two groups by randomized numerical table method: the observation group and the control group. The observation group was given letrozole and the control group was given tamoxifen. At the end of the medication, the results of each index of the two groups were compared. Results: After medication, The Kupperman score of the observation group was lower and Karnofsky Performance Scale (KPS) score was higher compared to the control group (P < 0.05). Besides, the high-density lipoprotein cholesterol (HDL-C) level of the observation group was higher than that of the control group after treatment (P < 0.05). Moreover, the adherence to medication and regular follow-up rate of the observation group was higher than that of the control group (P < 0.05). Lastly, all liver function indexes of the observation group were lower than those of the control group after treatment (P < 0.05). Conclusion: Letrozole is more effective in treating breast cancer patients who are undergoing postoperative endocrine therapy, with less impact on blood lipids and liver function. Therefore, it is worthy of further research and application.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
